Swapping the bottle for a gummy is the most common reason people land on this page, and it is the plan the evidence supports least. Alcohol withdrawal can bring seizures and a delirium that needs hospital care. The American Society of Addiction Medicine's 2020 guideline on withdrawal treats it with benzodiazepines, and no cannabinoid appears in any of its recommendations. The guideline's authors left cannabinoids out of the evidence review entirely, filed beside sodium oxybate and clomethiazole as drugs not widely available in the United States.
Our position is plain. An edible has no role in getting someone off alcohol, and the case for it as a long-term substitute rests mostly on surveys of people who already liked cannabis. The CBD story is thinner than the shelf suggests: the two randomized trials that followed drinking for weeks gave people with alcohol use disorder up to 1,200mg a day, and CBD did no better than placebo on drinking. What follows is what was studied, what was found, and the two medications that have the trial record cannabis lacks.
Can cannabis help with alcohol withdrawal?
No clinical guideline lists it, and no trial has tested it. The ASAM guideline names benzodiazepines as first-line treatment because they reduce withdrawal seizures and delirium, with phenobarbital, carbamazepine or gabapentin for patients who cannot take them. Cannabinoids were excluded from the evidence review before a single recommendation was written.
The guideline's timeline explains why withdrawal is no place for home experiments. Symptoms typically start 6 to 24 hours after the last drink, or after a sharp cut in drinking (which surprises people who planned a gentle taper on their own). Seizures can begin as early as 8 hours in and continue for up to 48, peaking around 24. Alcohol withdrawal delirium, the condition older textbooks called delirium tremens, appears 72 to 96 hours after the last drink and usually lasts two to three days. The guideline also notes that a seizure can arrive without the other prominent signs that would have warned anyone.
Each episode also tends to be worse than the one before. ASAM calls this kindling, and describes repeated withdrawals growing more severe, raising craving and blunting the response to benzodiazepines. A string of failed weekend detoxes is its own risk factor.
Now set an edible against that clock. On our edible timing guide, onset runs 30 minutes to 2 hours and the main effects last 4 to 8 hours. A gummy covers part of one evening in a syndrome that runs three to four days, against a seizure risk nobody in the guideline's evidence base tested it on. The guideline does ask clinicians to weigh other substance use when judging risk, noting that it can play a role in the life-threatening presentations, which is one more reason to say the word cannabis at intake.
Does replacing alcohol with cannabis work?
For some people in some studies, and the studies are mostly the weak kind. A 2020 systematic review of 64 human studies and one animal study counted 30 finding substitution, 17 finding the opposite, 14 finding neither and four finding both. Its verdict was mixed evidence that differs by population and by study design.
One of that review's authors, Subbaraman, had already tested the idea in 2014 against seven published criteria for a substitute medication for alcohol, in Alcohol and Alcoholism. Most of the criteria came out satisfied or partly satisfied, with a catch the paper spells out: much of the support came from medical cannabis patients, a self-selected group studied looking backward. The paper called the recommendation to give alcohol-dependent people cannabis to help them drink less premature.
The best-known survey in favor is Canadian. Lucas and colleagues surveyed 2,102 people in the national medical cannabis program and analyzed the 973 who had drunk alcohol at least 10 times in the year before they started. Afterward, 44% reported drinking less often and 8% reported no alcohol at all in the previous 30 days. Those are recalled numbers from people who chose cannabis and stayed with it, the group most likely to say it worked.
The cleanest point for substitution is a 2025 laboratory result. Sixty-one people who use both substances came in for two sessions, one with a priming drink alone and one after using legal-market cannabis, and were then offered up to four more drinks. After cannabis they drank fewer, and 23 of them were classed as substituters. That is one afternoon, supervised, in people who were not seeking treatment.
Then there is the group this page is actually about. Among 205 residents of 28 Los Angeles sober living houses, all with a lifetime alcohol use disorder, any cannabis use in the past 30 days went with 7.02 times the odds of any drinking, twice the drinking days and 3.21 times the odds of alcohol problems, after adjustment. The design cannot show which came first. It is still the opposite of what the swap predicts, in the people the swap is pitched at.
What happens when people drink and use cannabis at the same time?
Harm goes up, and mostly because drinking goes up. In 154 young adults who reported recent binge drinking, days with both substances brought more negative consequences than alcohol-only days. A 2026 daily study of 115 young adults found they drank more on co-use days, and the extra drinks explained the extra harm.
Substitution assumes one replaces the other, and national survey data show the two often travel together. Using the 2008 to 2019 National Survey on Drug Use and Health, Gonçalves and colleagues found simultaneous use rose among adults 21 to 50 after states opened recreational sales, by 1.75 percentage points in the 41-to-50 group. The authors read that as the complementary pattern, the reverse of a swap. For a fair number of people, the cannabis sold as a drink replacement is working as the chaser.
An edible makes the overlap easy to fall into, because a dose taken at dinner is still working when the second drink arrives. Our edibles and alcohol guide covers what the combination does in the body.
Is CBD good for quitting alcohol?
Not on the trial evidence so far. Two randomized trials from NYU, published in January 2026, gave 57 adults with alcohol use disorder CBD (600mg a day, rising to 1,200mg in one trial) or placebo. Both groups cut their drinking sharply, and CBD did no better than placebo on drinking, craving, mood, anxiety or PTSD symptoms.
The drug was 200mg capsules of hemp-derived CBD supplied by Tilray, taken twice a day, and it was not gentle. Seven of the 31 people assigned to CBD had side effects that limited their dose. Across the two trials, nausea hit 20% of the CBD group against none on placebo, and diarrhea 27% against 12%. For scale, 1,200mg is six of those capsules, or 48 gummies at 25mg apiece, which is a bag rather than a serving, and it still did nothing the placebo did not.
The positive result that gets quoted is a brain scan. In a Mannheim trial of 28 people with alcohol use disorder, a single 800mg dose of CBD dampened the amygdala's response to angry and fearful faces, and the people whose amygdalas reacted more also reported more craving. Nobody's drinking was followed over time. A Sydney crossover trial gave 800mg a day for three days and has reported twice this year: no effect on brain activity while anticipating a threat, and no effect on risky choices in a card task, alongside a rise in one heart rate variability measure whose meaning the authors call uncertain.
A 2026 systematic review of cannabinoids across mental and substance use disorders rated the alcohol evidence very limited, with certainty mostly very low across the whole review. A CBD gummy sold for cutting back on drinking is selling the brain scan and skipping the trial.
What has trial evidence for drinking less?
Naltrexone and acamprosate. A 2023 JAMA meta-analysis of 118 trials and 20,976 participants found that to keep one person from returning to any drinking, 11 people had to take acamprosate or 18 had to take 50mg of oral naltrexone. For return to heavy drinking, oral naltrexone's figure was 11.
Those are modest numbers, and they come with side effects the same paper counted: more diarrhea on acamprosate and more nausea and vomiting on naltrexone than on placebo. The authors called them first-line, alongside psychosocial treatment. The cannabinoid column holds two small proof-of-concept CBD trials in one paper, and both came up empty. Medication for alcohol use disorder is prescribed, and the person prescribing it needs to know about any cannabis in the picture.
What if I already use cannabis and want to cut down on drinking?
Tell the clinician about both, because the cannabis changes the assessment. ASAM asks clinicians to account for other substance use when judging withdrawal risk, and the sober living data put recent cannabis use alongside more drinking. Nothing here argues for stopping cannabis abruptly or for starting it. The point is to say it out loud.
THC brings its own problems into a recovery plan, from the psychiatric risks on our psychosis risk page to the plain fact that a second intoxicant makes a drinking diary harder to read. Negative affect is the driver the CBD researchers were chasing, since it feeds craving and relapse, and the evidence on cannabis for anxiety itself sits on our generalized anxiety page.